46K Stock Chart & Stats
€81.50
€0.00(0.00%)
At close: 4:00 PM EDT
€81.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€50.50 - €89.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€1.01B
Enterprise Value€1.18K
Total Cash (Recent Filing)€59.08M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)50.2
Beta0.33
Next Earnings
Oct 29, 2026EPS Estimate
0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.81
Shares Outstanding12,783,035
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio3.34
Price to Book (P/B)13.08
Price to Sales (P/S)14.77
P/FCF Ratio72.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.81
Revenue Forecast (FY)€79.76M
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high gross and net margins indicate durable pricing power and operating efficiency in a specialized MRI-compatible devices niche. Strong margins support reinvestment in R&D, fund dividends and buffer cyclic hospital spending, underpinning long-term earnings resilience.
Conservative Balance SheetAn essentially debt-free balance sheet gives the company low financial risk and flexibility to self-fund product ramps, absorb demand volatility, and pursue strategic initiatives without refinancing pressure, strengthening long-term capital allocation options.
Strong Cash GenerationRobust trailing cash flow and free cash flow enable sustainable investment in manufacturing scale, R&D and recurring revenue drivers (disposables, service). Consistent FCF supports dividends and internal growth funding, reducing reliance on external capital over time.
Bears Say
Decelerating Revenue GrowthTop-line deceleration from prior rapid growth raises risk the company may struggle to meet elevated expectations absent sustained 3870 adoption. Slower revenue momentum can constrain operating leverage and limits the pace at which recurring consumables and service revenue scale.
Execution Risk On 3870 RampA deliberately cautious manufacturing ramp creates timing risk for realizing projected pump run-rates and related disposables revenue. Scaling production, stabilizing supply chains and transferring know-how are multi-quarter tasks that can delay revenue recognition and margin expansion.
Geographic ConcentrationHeavy U.S. concentration concentrates exposure to a single healthcare market's capital spending cycles, reimbursement dynamics, and regulatory shifts. Limited international diversification could cap long-term addressable market growth and increase revenue cyclicality.
Iradimed News
46K FAQ
What was Iradimed Corp’s price range in the past 12 months?
Iradimed Corp lowest stock price was €50.50 and its highest was €89.50 in the past 12 months.
What is Iradimed Corp’s market cap?
Iradimed Corp’s market cap is €1.01B.
When is Iradimed Corp’s upcoming earnings report date?
Iradimed Corp’s upcoming earnings report date is Oct 29, 2026 which is in 88 days.
How were Iradimed Corp’s earnings last quarter?
Iradimed Corp released its earnings results on Jul 31, 2026. The company reported €0.399 earnings per share for the quarter, beating the consensus estimate of €0.381 by €0.017.
Is Iradimed Corp overvalued?
According to Wall Street analysts Iradimed Corp’s price is currently Overvalued.
Does Iradimed Corp pay dividends?
Iradimed Corp does not currently pay dividends.
What is Iradimed Corp’s EPS estimate?
Iradimed Corp’s EPS estimate is 0.47.
How many shares outstanding does Iradimed Corp have?
Iradimed Corp has 12,783,035 shares outstanding.
What happened to Iradimed Corp’s price movement after its last earnings report?
Iradimed Corp reported an EPS of €0.399 in its last earnings report, beating expectations of €0.381. Following the earnings report the stock price went up 0.613%.
Which hedge fund is a major shareholder of Iradimed Corp?
Currently, no hedge funds are holding shares in DE:46K
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Iradimed Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:46K Sentiment 70%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €247.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.17%
12-Months-Change
Fundamentals
Return on Equity
1.29%
Trailing 12-Months
Asset Growth
12.44%
Trailing 12-Months
Company Description
Iradimed Corp
IRADIMED CORPORATION specializes in the engineering, production, and distribution of medical devices specifically designed for compatibility with magnetic resonance imaging (MRI) environments. The company supplies these specialized products, alongside their related accessories and support services, to both U.S. and international markets. Key offerings include the MRidium MRI-compatible intravenous (IV) infusion pump system, which comes with disposable tubing sets, and an MRI-compatible patient vital signs monitoring system. Furthermore, IRADIMED provides a range of complementary items such as non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring solutions with sensors. Their clientele primarily consists of hospitals, acute care facilities, and outpatient imaging centers. Sales are conducted via direct field representatives, regional sales directors, clinical support specialists, and independent distributors. Founded in 1992, IRADIMED CORPORATION is headquartered in Winter Springs, Florida.
46K Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong Q1 financial results (13% revenue growth, 33% operating income growth, double-digit net income improvement), healthy margins, substantial cash generation, and an encouraging early 3870 product launch with higher-than-expected ASP and quad-system demand. Near-term headwinds are primarily transitional and execution-related: a planned conservative manufacturing ramp (130–135 3870s in Q2) leads to guidance showing a modest Q2 revenue dip versus Q1, and there are temporary tax and R&D expense effects. These lowlights appear manageable relative to the magnitude of the reported financial improvements and the sizeable replacement opportunity for the 3870, so positive momentum is the dominant theme.View all DE:46K earnings summaries